Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...

Descrición completa

Detalles Bibliográficos

Principais autores:	Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2017-09-01
Series:	Human Vaccines & Immunotherapeutics
Assuntos:	adults india immunogenicity safety thirteen-valent pneumococcal conjugate vaccine
Acceso en liña:	http://dx.doi.org/10.1080/21645515.2017.1331796
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!